Drug profile · INN
niraparib tosylate
ZEJULA
niraparib tosylate (ZEJULA) is a poly [adp-ribose] polymerase 2 inhibitor. Route of administration: oral. Current US regulatory status: approved.
Drug details — niraparib tosylate
- US status
- approved
- Class
- —
- Route
- ORAL
- Patents
- 0
- Programs
- 8
- Data quality
- 0.84
Quick answer
niraparib tosylate (ZEJULA) is a poly [adp-ribose] polymerase 2 inhibitor. Route of administration: oral. Current US regulatory status: approved.
Key facts
Mechanism of action
Poly [ADP-ribose] polymerase 2 inhibitor
Primary target: Poly [ADP-ribose] polymerase 2
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
Pipeline programs
Related & competitor drugs
Frequently asked questions
What is niraparib tosylate?
niraparib tosylate (ZEJULA) is a poly [adp-ribose] polymerase 2 inhibitor. Route of administration: oral. Current US regulatory status: approved.
What is the brand name for niraparib tosylate?
ZEJULA is a marketed brand name for niraparib tosylate. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of niraparib tosylate?
niraparib tosylate has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.